Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 9/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CBLB | Q13191 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136129 | 1.00 | KMO (0.37) | KMOCNR2ABL1PDE2ANPC1 | |
| SCHEMBL25136085 | 0.98 | KMO (0.37) | KMOCNR2ABL1PDE2A | |
| SCHEMBL25136213 | 0.86 | CNR2 (0.33) | KMOCNR2ABL1PDE2ANPC1 | |
| SCHEMBL25136211 | 0.86 | CBLB (0.40) | CBLB | |
| SCHEMBL25136301 | 0.86 | CBLB (0.40) | CBLB | |
| SCHEMBL25136058 | 0.86 | CNR2 (0.33) | KMOCNR2ABL1PDE2ANPC1 | |
| SCHEMBL25136176 | 0.83 | ALDH1A1 (0.36) | CNR2PDE2ARAB9A | |
| SCHEMBL25136256 | 0.83 | KMO (0.37) | KMOCNR2ABL1CBLB | |
| SCHEMBL25136125 | 0.82 | NPC1 (0.35) | CNR2PDE2ANPC1RAB9ACBLB | |
| SCHEMBL25136397 | 0.82 | KHK (0.39) | CNR2PDE2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | KMO 3243/4885CNR2 547/4885ABL1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.